A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

Key facts

Sponsor

UCB Biopharma SRL

Principal Investigator

UCB Cares

001 844 599 22733 (UCB)

Intervention

Bimekizumab(drug)

Enrollment

300 enrolled

Eligibility

18 years · All sexes

Timeline

2025 – 2029

Study locations (30)

• Ppp001 50233, Barrie, Canada
• Ppp001 50749, Fredericton, Canada
• Ppp001 50765, London, Canada
• Ppp001 50740, Québec, Canada
• Ppp001 50752, Red Deer, Canada
• Ppp001 50750, Surrey, Canada
• Ppp001 20357, Beijing, China
• Ppp001 20137, Chengdu, China
• Ppp001 20352, Chengdu, China
• Ppp001 20350, Chongqing, China
• Ppp001 20313, Guangzhou, China
• Ppp001 20022, Hangzhou, China
• Ppp001 20355, Jinan, China
• Ppp001 20345, Shanghai, China
• Ppp001 20184, Shenzhen, China
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Pustulosis palmaris et plantaris

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONPHASE4NCT07513142
  PPP Versus Corticosteroid for Thigh Muscle Injuries
  Andrews Research & Education Foundation
• RECRUITINGPHASE4NCT07503652
  Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar Pustulosis
  First Hospital of China Medical University
• RECRUITINGNANCT07270003
  A Prospective, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Ivarmacitinib in the Treatment of Palmoplantar Pustulosis
  Xijing Hospital
• RECRUITINGPHASE2NCT07013201
  A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
  LEO Pharma

See all trials for Pustulosis palmaris et plantaris →